Buprenorphine for Chronic Pain: a Systemic Review

  • Michael A. FishmanEmail author
  • Phillip S. Kim
Anesthetic Techniques in Pain Management (D Wang, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Anesthetic Techniques in Pain Management


Purpose of Review

The purpose of this review is to evaluate and explain our current understanding of the clinical use of buprenorphine in the treatment of chronic pain.

Recent Findings

There has been few high-quality, unbiased studies performed on the use of buprenorphine in the treatment of chronic pain.


Buprenorphine is an effective and safe analgesic that is tolerated at least as well, if not better, than other opioids. Given its safety and mechanistic advantages, the authors believe there is an important role for buprenorphine in the treatment of chronic pain severe enough to warrant the use of an opioid analgesic. Though data is lacking for superiority in chronic pain states, the other advantages of the molecule make it the preferential first-line opioid for around-the-clock pain in our practice.


Buprenorphine Chronic pain 


Compliance with Ethical Standards

Conflict of Interest

Dr. Fishman reports personal fees and sponsored research from Medtronic, Inc. and Biotronik, Inc. He reports personal fees from Nevro, Inc. and Depomed and sponsored research from Stimgenics, LLC, all of which are outside the submitted work. Dr. Kim reports that he is on the speaker bureau for Jazz and Collegium. He is also a consultant for Medtronic and Biotronik, and has done research for Medtronic, Stimgenics, and Vertiflex. Dr. Kim is on the medical board of CBsync and Agrokind.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Institute of Medicine. Relieving Pain in America: a Blueprint for Transforming Prevention, Care, Education, and Research. Vol. 26, Journal of Pain & Palliative Care Pharmacotherapy. Washington, DC: The National Academies Press; 2012.Google Scholar
  2. 2.
    Centers for Disease Control. Annual Surveillance Report Of Drug-related Risks And Outcomes [Internet]. 2017 [cited 2018 Apr 13]. Available from:
  3. 3.
    Centers for Disease Control. Prescription Opioid Overdose Data [Internet]. [cited 2018 Apr 13]. Available from:
  4. 4.
    Pattinson KTS. Opioids and the control of respiration. Br J Anaesth Oxford University Press. 2008;100(6):747–58.CrossRefGoogle Scholar
  5. 5.
    Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain—United States, 2016.[Erratum appears in MMWR Recomm Rep. 2016;65(11):295]. Morb Mortal Wkly Report Recomm Reports. 2016;65(1):1–49.Google Scholar
  6. 6.
    • Pergolizzi J, Aloisi AM, Dahan A, Filitz J, Langford R, Likar R, et al. Current knowledge of buprenorphine and its unique pharmacological profile. Pain Pract. 2010;10(5):428–50 A rational look at the pharmacological properties of buprenorphine that addresses common misconceptions. CrossRefGoogle Scholar
  7. 7.
    Gordon A, Callaghan D, Spink D, Cloutier C, Dzongowski P, O’Mahony W, et al. Buprenorphine transdermal system in adults with chronic low back pain: a randomized, double-blind, placebo-controlled crossover study, followed by an open-label extension phase. Clin Ther Excerpta Medica Inc. 2010;32(5):844–60.CrossRefGoogle Scholar
  8. 8.
    Yoon DH, Bin S-I, Chan SK-C, Chung CK, In Y, Kim H, et al. Effectiveness and tolerability of transdermal buprenorphine patches: a multicenter, prospective, open-label study in Asian patients with moderate to severe chronic musculoskeletal pain. BMC Musculoskelet Disord. BMC Musculoskelet Disord. 2017;18(1):337.CrossRefGoogle Scholar
  9. 9.
    Gimbel J, Spierings ELH, Katz N, Xiang Q, Tzanis E, Finn A. Efficacy and tolerability of buccal buprenorphine in opioid-experienced patients with moderate to severe chronic low back pain: results of a phase 3, enriched enrollment, randomized withdrawal study. PainPain. 2016;157(11):2517–26.CrossRefGoogle Scholar
  10. 10.
    Reckitt Benckiser Pharmaceuticals. Buprenex (buprenorphine hydrochloride) injection, solution. 2007.Google Scholar
  11. 11.
    Yarlas A, Miller K, Wen W, Lynch SY, Ripa SR, Pergolizzi J V, et al. Buprenorphine transdermal system improves sleep quality and reduces sleep disturbance in patients with moderate-to-severe chronic low Back pain : results from two randomized controlled trials. Pain Pract 2015;541(Trial I).Google Scholar
  12. 12.
    Pergolizzi J, Aloisi AM, Dahan A, Filitz J, Langford R, Likar R, et al. Current knowledge of buprenorphine and its unique pharmacological profile. Pain Pract. 2010;10(5):428–50.CrossRefGoogle Scholar
  13. 13.
    •• Davis MP. Twelve reasons for considering buprenorphine as a frontline analgesic in the management of pain. J Support Oncol. 2012;10(6):209–19 An excellent review on the compelling safety and practical reasons to use buprenorphine as a first-line agent for treating pain. CrossRefGoogle Scholar
  14. 14.
    Bai SA, Xiang Q, Finn A. Evaluation of the pharmacokinetics of single- and multiple-dose buprenorphine buccal film in healthy volunteers. Clin Ther Elsevier. 2016;38(2):358–69.CrossRefGoogle Scholar
  15. 15.
    Dahan A. Opioid-induced respiratory effects: new data on buprenorphine. Palliat MedPalliat Med. 2006;20(Suppl 1):s3–8.Google Scholar
  16. 16.
    Plosker GL. Buprenorphine 5, 10 and 20 mug/h transdermal patch: a review of its use in the management of chronic non-malignant pain. DrugsDrugs. 2011;71(18):2491–509.CrossRefGoogle Scholar
  17. 17.
    Yassen A, Olofsen E, Kan J, Dahan A, Danhof M. Pharmacokinetic–pharmacodynamic modeling of the effectiveness and safety of buprenorphine and fentanyl in rats. 2007;CrossRefGoogle Scholar
  18. 18.
    Raffa RB, Haidery M, Huang HM, Kalladeen K, Lockstein DE, Ono H, et al. The clinical analgesic efficacy of buprenorphine. J Clin Pharm TherJ Clin Pharm Ther. 2014;39(6):577–83.CrossRefGoogle Scholar
  19. 19.
    Tompkins DA, Smith MT, Mintzer MZ, Campbell CM, Strain EC. A double blind, within subject comparison of spontaneous opioid withdrawal from buprenorphine versus morphine s. J Pharmacol Exp Ther J Pharmacol Exp Ther. 2014;348:217–26.CrossRefGoogle Scholar
  20. 20.
    Jonan AB, Kaye AD, Urman RD. Buprenorphine formulations: clinical best practice strategies recommendations for perioperative management of patients undergoing surgical or interventional pain procedures. Pain physician3. 2018;21(1):E1–12.Google Scholar
  21. 21.
    Greenwald MK, Comer SD, Fiellin DA. Buprenorphine maintenance and mu-opioid receptor availability in the treatment of opioid use disorder: implications for clinical use and policy. Drug Alcohol DependDrug Alcohol Depend. 2014;144:1–11.CrossRefGoogle Scholar
  22. 22.
    Endo Pharmaceuticals I. Belbuca prescribing information. 2015;Google Scholar
  23. 23.
    Purdue Pharma LP. Butrans prescribing Inform 2014;(5).Google Scholar
  24. 24.
    • Rauck RL, Potts J, Xiang Q, Tzanis E, Finn A. Efficacy and tolerability of buccal buprenorphine in opioid-naive patients with moderate to severe chronic low back pain. Postgrad Med Taylor & Francis. 2016;128(1):1–11 A study that highlights the average therapeutic dose in opioid-naïve patients for chronic low back pain. CrossRefGoogle Scholar
  25. 25.
    Wallace L, Kadakia A. Buprenorphine transdermal system utilization. Postgrad Med Taylor & Francis. 2017;129(1):81–6.CrossRefGoogle Scholar
  26. 26.
    Simpson RW, Wlodarczyk JH. Transdermal buprenorphine relieves neuropathic pain: a randomized, double-blind, parallel-group, placebo-controlled trial in diabetic peripheral neuropathic pain. Diabetes CareDiabetes Care. 2016;39(9):1493–500.CrossRefGoogle Scholar
  27. 27.
    Sigmon SC, Moody DE, Nuwayser ES, Bigelow GE. An injection depot formulation of buprenorphine: extended biodelivery and effects. AddictionAddiction. 2006;101(3):420–32.CrossRefGoogle Scholar
  28. 28.
    Schmidt-Hansen M, Bromham N, Taubert M, Arnold S, Hilgart JS. Buprenorphine for treating cancer pain. Cochrane Database Syst RevCochrane Database Syst Rev. 2015;3:CD009596.Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Center for Interventional Pain and SpineWilmingtonUSA

Personalised recommendations